Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de Fase 1/2 de BHB810 en Adenocarcinoma Gástrico Avanzado y de la Unión Gastroesofágica

19 de octubre de 2026 actualizado por: BigHat Biosciences, Inc.

Estudio de Fase 1/2, Abierto, Multicéntrico, de Escalada de Dosis y Expansión de BHB810 en Participantes con Adenocarcinoma Gástrico Avanzado y de la Unión Gastroesofágica

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

164

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • Duarte, California, Estados Unidos, 91010
        • Reclutamiento
        • City of Hope Duarte
        • Investigador principal:
          • Dani Castillo, MD
        • Contacto:
          • Jalene Tangen
          • Número de teléfono: 833-917-5715
          • Correo electrónico: jtangen@coh.org
      • Santa Monica, California, Estados Unidos, 90404
        • Aún no reclutando
        • University of California at Los Angeles
        • Investigador principal:
          • Zev Wainberg, MD
        • Contacto:
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Reclutamiento
        • NEXT Virginia
        • Investigador principal:
          • Alexander Spira, MD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.

  • Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.

    • Participants in Phase 1 Backfill Cohorts & Phase 2 must be CDH17-positive by central testing.
    • Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
  • At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)

  • Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.

  • Adequate organ and marrow function as defined in the protocol

Exclusion Criteria:

  • Prior cancer treatment as follows, relative to the first planned dose of trial intervention:

    • Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
    • Monoclonal antibody-based therapy (including ADCs) within 4 weeks
    • Immune checkpoint inhibitors within 4 weeks
    • Wide-field radiation therapy (>30% marrow-bearing bones) within 4 weeks or < 2 weeks of focal palliative radiation to nontarget lesions
  • Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)

  • Known hypersensitivity or allergic reaction to BHB810 or it's excipients

  • Left ventricular ejection fraction <50% or history of congestive heart failure Class III/IV

  • QTc interval > 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc

  • Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant

  • Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.

  • Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention

  • Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Dose Escalation and Backfill Cohorts

Dose escalation and backfill cohorts

Every 2 weeks IV administration

Experimental: Recommended Phase 2 Dose Level 1 (RP2D1)

Dose level 1 of 2 prospective recommended phase 2 dose levels

Every 2 weeks IV administration

Experimental: Recommended Phase 2 Dose Level 2 (RP2D2)

Dose level 2 of 2 prospective recommended phase 2 dose levels

Every 2 weeks IV administration

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v6.0)
Periodo de tiempo: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months

Investigate the safety and tolerability of BHB810 by evaluation of AEs, SAEs, DLTs, and clinically significant changes safety assessments, like lab tests, vital signs, and other safety assessments

Phase 1 (Dose Escalation & Backfill Cohorts) and Phase 2 (Dose Optimization)

DLTs apply to Phase 1 Dose Escalation Cohorts only.

Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
Incidence of participants who have a dose modification of BHB810 due to toxicity
Periodo de tiempo: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months

Investigate the safety and tolerability of BHB810 by assessment of dose modifications due to toxicity

Phase 1 (Dose Escalation & Backfill Cohorts)

Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
Overall Response Rate (ORR)
Periodo de tiempo: Screening through End of Treatment, an average of 6 months

Identify the recommended Phase 2 dose (RP2D) by comparing 2 doses of BHB810 by evaluating the ORR of participants according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Phase 2 (Dose Optimization)

Screening through End of Treatment, an average of 6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical Benefit Rate (CBR)
Periodo de tiempo: Screening through End of Treatment, an average of 6 months

Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1

Number of participants who achieve stable disease (SD) for at least 6 months, or PR or CR for any duration

Phase 1 (Dose Escalation & Backfill Cohorts)

Screening through End of Treatment, an average of 6 months
Duration of Response (DOR)
Periodo de tiempo: Screening through End of Treatment or last scan, an average of 6 months

Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1

Time from PR or CR to disease progression

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

Screening through End of Treatment or last scan, an average of 6 months
Progression Free Survival (PFS)
Periodo de tiempo: Screening through End of Treatment, an average of 6 months

Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1

Time from first dose to first documented date of progression per RECIST v1.1

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

Screening through End of Treatment, an average of 6 months
Overall Survival (OS)
Periodo de tiempo: Screening through End of Study, an average of 10 months

Investigate preliminary antitumor activity of BHB810

Time from first dose to death from any cause

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

Screening through End of Study, an average of 10 months
Pharmacokinetics: Area under the concentration-time curve (AUC)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Area under the concentration-time curve from zero to the end of a dosing interval at steady-state (AUC0-tau)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Maximum concentration of BHB810 (Cmax) Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Time to reach maximum drug concentration of BHB810 (Tmax)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Area under the concentration-time curve from zero to infinity (AUC0-inf)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Terminal elimination half-life (t1/2)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Volume of drug distribution during terminal phase (Vz)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Total body clearance of the drug (CL)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Area under the concentration-time curve from zero to last measurable concentration sample time (AUC0-last)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Incidence of antidrug antibodies (ADAs) in blood before and after BHB810 administration
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the ADAs and PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de julio de 2026

Finalización primaria (Estimado)

1 de diciembre de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

1 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

7 de abril de 2026

Publicado por primera vez (Actual)

14 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir